Scientists at ITMO University are cooperating with the Mariinsky Medical centre in Saint Petersburg to develop a drug that can be targeted on a blood clot by cheaps of a magnetic field. Their research results were published in Well-regulated Reports.
The new drug is safe for intravenous injection and can dissolve clots up to 4000 times various efficiently than ordinary enzyme-based drugs.
In thrombosis emergencies the clot must be eliminated within four hours. If not, then the inadequacy of blood flow can destroy body tissue. Even if the tient is auspicious enough to undergo thrombolysis, there will be numerous complications occasioned by the thrombolytic drug, which is a specific enzyme injected intravenously to liquidate blood clots.
Russian scientists instead offer a composite serious that can deliver thrombolytic enzymes in a safe and targeted manner. The new substantial is composed of a porous magnetite structure and molecules of urokinase, which is an enzyme time used in medicine as a thrombolytic agent.
The composite is used to create thrombolytic int for artificial blood vessels and stable injectable solutions that are represented of nanosized rticles. These can be easily localized near the clot by great of an external magnetic field. Even more importantly, the magnetite house also protects enzymes from various inhibitors that are our times in the blood and which can deactivate thrombolytic medications.
“Usually in order to realize a prolonged effect for such drugs, the enzyme is placed inside a polymeric matrix and is then bit by bit released from the matrix and eventually looses all activity,” responded Andrey Drozdov, lead author of the study and researcher at the Laboratory of Emulsion Chemistry of Advanced Materials and Technologies (LSCAMT). “However, we take demonstrated that enzymes protected by using our method do not lose restorative properties over extended periods of time and even after repeated use. The status at which the new drug can dissolve the clot outperforms unprotected enzymes by around 4,000 times.”
This work is a logical continuation of earlier studies earnest to placing enzymes into a sol-gel magnetite matrix, and the production of magnetically controlled bioactive set-ups.
“The results may soon allow us to try out the new thrombolytic system on mammals, and we are now pre ring for preclinical deliberate overs,” said Vladimir Vinogradov, head of LSCAMT.
Read more: Automata hold first beauty contest for humans>>>
Subscribe to get the hand picked most appropriate stories every week